Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Enters LAA Closure Market In Earnest With Coherex Buy

This article was originally published in The Gray Sheet

Executive Summary

J&J's Biosense Webster heart-rhythm device unit has acquired privately held partner Coherex Medical, solidifying its stake in the left atrial appendage closure market that Boston Scientific currently leads.

You may also be interested in...



Who's Next? Emerging LAA Closure Devices

As first-to-market in the US with a transcatheter left atrial appendage closure device, Boston Scientific has blazed a regulatory and reimbursement trail for other companies in this space and opened up a potentially billion-dollar-plus market. In this second part of our two-part series on LAAC devices, Medtech Insight reports on other companies with current and emerging LAAC devices and looks at how close they are to bringing their technology to the US market.

Upgraded Paige Suite Gains CE-IVD and UKCA Marks

Paige’s AI has obtained CE-IVD and UKCA marks, allowing the launch of a breakthrough product that can spot biomarkers from images.

Sanofi Scores In Second-Line Myeloma But Still In Darzalex’s Shadow

The French company believes it has the best-in-class CD38 antibody with new PFS data, but Johnson & Johnson and Genmab’s Darzalex looks set to retain its advantage in multiple myeloma.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT034400

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel